New articles highlighting phase III data on the IL-13 inhibitor tralokinumab from Leo Pharma A/S have shown that combining it with topical corticosteroids as needed was effective and well-tolerated in patients with moderate to severe atopic dermatitis. Read More
Dren Bio Inc. has closed on a $60 million series A to push its two lead programs through early clinical development. The company’s DR-01 is an antibody-based therapy for treating rare leukemias, lymphomas and specific phenotypes of autoimmune disorders. The company said it is initially targeting neglected hematology-oncology indications. Read More
Even though the appetite for biopharma IPOs this year has been voracious with no signs of a slowdown anytime soon, companies also have a potentially faster route to the public market using special purpose acquisition companies (SPAC) that raise money through an IPO in order to take a company public through an acquisition. Read More
Cambridge, U.K.-based Bicycle Therapeutics plc’s phase I dosing about a month ago of its first patient with nectin-4-targeting BT-8009 put the company on the road to hoped-for success by pursuing the same mechanism of action as Padcev (enfortumab vedotin-ejfv), the antibody-drug conjugate (ADC) from Astellas Pharma Inc. and Seagen Inc. Read More
HONG KONG – Yongin, South Korea-based Rznomics Inc. is on track to develop adenoviruses for gene therapies, after signing a clinical and commercial agreement with Cologne, Germany based-Cevec Pharmaceuticals GmbH. The partnership will use the German company’s Cap technology to manufacture the adenoviruses, while the therapies, targeting various cancer indications, will be developed using Rznomics’ trans-splicing ribozyme technology. Read More
A multi-institutional team of researchers has implicated lipid droplets, which are key energy storage units of individual cells, in innate immune defense. Read More
New hires and promotions in the biopharma industry, including: Aveo, Histogen, Inflection, Nervgen, Nimbus, Oncolytics, Snipr Biome, Tollys, Topas. Read More
Biopharmas raising money in public or private financings, including: Betterlife, Cybin, Eton, Foghorn, IMV, In8bio, NLS, ONK, Scholar Rock, Solarea, Topas. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apellis, Aptose, Intrabio, Leo, Merck & Co., Midatech, Sobi, Ultimovacs, Velosbio. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Agios, Astrazeneca, Bristol Myers Squibb, Dr. Reddy's, Edesa, Exelixis, Genentech, Gilead, Intellia, Matinas, Mereo, Neurelis, Octapharma, Oncopeptides, Prestige, Recce, Roche, Versantis. Read More
